Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million, converting a regulatory asset into a substantial non‑dilutive cash infusion. The transaction, completed on April 26, 2026, provides the company with additional liquidity that extends its cash runway into the second quarter of 2028, giving management a longer horizon to advance its cardiovascular gene‑therapy pipeline.
The voucher was earned when the FDA granted accelerated approval to KRESLADI (marnetegragene autotemcel) for severe LAD‑I on March 27, 2026. The approval marked the first gene therapy for this rare pediatric condition and triggered the voucher award, which Rocket has now monetized. The sale price of $180 million aligns with recent market activity, following a peak of around $200 million for similar vouchers earlier in 2026.
Rocket’s CEO, Gaurav Shah, said the proceeds will be earmarked for its clinical‑stage cardiovascular programs, including Danon disease, PKP2‑associated arrhythmogenic cardiomyopathy, and BAG3‑associated dilated cardiomyopathy. The infusion of capital allows the company to focus on key clinical milestones without the immediate pressure of additional financing, strengthening its position for potential commercial launch and future partnership opportunities.
Prior to the sale, Rocket’s cash position had been under pressure. In Q1 2025 the company reported $318.2 million in cash, which was projected to fund operations into Q4 2026. By Q4 2025, cash had fallen to $188.9 million, with a projected runway into Q2 2027. The $180 million voucher sale therefore extends the runway by roughly 18 months, a significant buffer for a clinical‑stage biotech company with high R&D expenses.
The transaction also highlights the continued strategic value of the Rare Pediatric Disease Priority Review Voucher program, which was reauthorized in February 2026. Rocket’s sale price reflects a slight cooling from the $200 million peak seen earlier in the year, but remains among the highest in the market, underscoring the voucher’s role as a valuable non‑dilutive financing tool for companies developing treatments for rare pediatric disorders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.